[A 72 week follow-up study of chronic hepatitis C patients treated with peginterferon alfa-2b and ribavirin].
Yu
Shu-li
SL
Hospital of Infectious Diseases of Jinan, Jinan 250021, China. yushuli999@126.com
Zhang
Zhao-hua
ZH
Lv
Hui
H
Zhang
Qin-gang
QG
Wang
Yao-zong
YZ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D055815:Young Adult
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b